LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Inicio・Lista de Acciones・Gossamer Bio Inc

Gossamer Bio Inc

Cerrado

SectorSanidad

0.21 5

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.2

Máximo

0.23

Métricas clave
By Trading Economics
Ingresos	574K -47M
Ventas	3.2M 17M
BPA	-0.2
Margen de beneficios	-275.223
Empleados	161
EBITDA	1.2M -45M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+2433.33% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-30M 49M
Apertura anterior	-4.79
Cierre anterior	0.21

Noticias sobre sentimiento de mercado

By Acuity

50%

154 / 344 Clasificación en Healthcare

Gossamer Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 may 2026, 16:52 UTC

Noticias de Eventos Importantes

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 may 2026, 23:57 UTC

Ganancias

Sociedad Quimica 1Q Rev $1.76B >SQM

26 may 2026, 23:57 UTC

Ganancias

Sociedad Quimica 1Q EPS $1.28 >SQM

26 may 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 may 2026, 21:54 UTC

Ganancias

Webco Industries 3Q EPS $11.61 >WEBC

26 may 2026, 21:54 UTC

Ganancias

Webco Industries 3Q Sales $179.6M >WEBC

26 may 2026, 21:48 UTC

Charlas de Mercado

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 may 2026, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

26 may 2026, 20:58 UTC

Adquisiciones, fusiones, absorciones

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

26 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

26 may 2026, 19:22 UTC

Charlas de Mercado

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 may 2026, 19:17 UTC

Charlas de Mercado

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 may 2026, 18:56 UTC

Charlas de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 may 2026, 18:03 UTC

Charlas de Mercado

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 may 2026, 17:42 UTC

Charlas de Mercado

Grains Await Fresh Trading Catalyst -- Market Talk

26 may 2026, 17:33 UTC

Charlas de Mercado

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 may 2026, 17:21 UTC

Charlas de Mercado

Canada Faces a Labor Market Squeeze -- Market Talk

26 may 2026, 16:52 UTC

Charlas de Mercado

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 may 2026, 16:43 UTC

Charlas de Mercado

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 may 2026, 16:24 UTC

Charlas de Mercado

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 may 2026, 16:21 UTC

Charlas de Mercado

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Auto & Transport Roundup: Market Talk

26 may 2026, 16:16 UTC

Charlas de Mercado

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 may 2026, 16:01 UTC

Charlas de Mercado

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 may 2026, 15:21 UTC

Charlas de Mercado

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc previsión

Precio Objetivo

By TipRanks

2433.33% repunte

Estimación a 12 Meses

Media 5.32 USD 2433.33%

Máximo 15 USD

Mínimo 0.28 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Gossamer Bio Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

154 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.